Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir
Autore:
Smee, DF; Bailey, KW; Wong, MH; Sidwell, RW;
Indirizzi:
Utah State Univ, Dept Anim Dairy & Vet Sci, Inst Antiviral Res, Logan, UT 84322 USA Utah State Univ Logan UT USA 84322 nst Antiviral Res, Logan, UT 84322 USA
Titolo Testata:
ANTIVIRAL RESEARCH
fascicolo: 3, volume: 47, anno: 2000,
pagine: 171 - 177
SICI:
0166-3542(200009)47:3<171:ITOCVR>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
HPMPC CIDOFOVIR; INFLUENZA-A; NEURAMINIDASE; INHIBITOR; EFFICACY; SAFETY;
Keywords:
antiviral; cidofovir; cowpox virus; intranasal treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Smee, DF Utah State Univ, Dept Anim Dairy & Vet Sci, Inst Antiviral Res, Logan, UT 84322 USA Utah State Univ Logan UT USA 84322 iral Res, Logan, UT 84322 USA
Citazione:
D.F. Smee et al., "Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir", ANTIVIR RES, 47(3), 2000, pp. 171-177

Abstract

Orthopoxvirus infections in mice have been effectively treated with cidofovir, a clinically approved drug given by intravenous infusion to treat cytomegalovirus infections. In a bioterrorist scenario it would be technically difficult to give this drug to a large number of exposed individuals. New treatment approaches are being sought, which include giving cidofovir by alternative routes or designing oral prodrugs of cidofovir. In this report, intranasal cidofovir was investigated as a treatment of pulmonary cowpox virus infections in BALB/c mice. Ninety to 100% of animals given a single intranasal drug treatment (10, 20 or 40 mg/kg) 24 h after virus challenge survived the infection, whereas all placebo-treated mice died. Doses of 2.5 and 5mg/kg resulted in 60 and 80% survival, respectively. Single treatments of 70 and 40 mg/kg could be given up to 3 days after virus inoculation and still be 80-90% protective. A single 40 mg/kg treatment of infected mice given1 or 2 days after infection also resulted in statistically significant decreases in virus titer in lungs and nose/sinus compared to the placebo group. Drug efficacy was found to be contingent upon treatment volume. A 10 mg/kg intranasal dose given 24 h after virus challenge was 100 and 50% effective in volumes of 40 and 20 mu l, respectively. The same dose in 5 and 10 mu l volumes caused no decrease in mortality. The results of these studies establish the utility of cidofovir treatment of poxvirus infections in mice byintranasal route. The data suggest the possibility that aerosol delivery of cidofovir to human lungs may be a viable alternative to intravenous dosing. (C) 2000 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 11:57:32